Yıl: 2020 Cilt: 35 Sayı: 2 Sayfa Aralığı: 300 - 302 Metin Dili: İngilizce DOI: 10.46497/ArchRheumatol.2020.7555 İndeks Tarihi: 13-10-2020

Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment

Öz:
-
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
  • 1. Uchida S, Oiso N, Komeda Y, Kudo M, Kawada A. Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. Eur J Dermatol 2018 Nov 13.
  • 2. Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab. J Crohns Colitis 2018 May 9.
  • 3. Wang J, Bhatia A, Krugliak Cleveland N, Gupta N, Dalal S, Rubin DT, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J 2018;5:e56.
  • 4. Ehrlich D, Jamaluddin N, Pisegna J, Padua D. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med 2018;2018:9679287.
  • 5. Shiga H, Fukuda S, Iijima K. Interleukin-17A inhibitorinduced Crohn’s Disease/Behçet’s disease-like lesions. Inflamm Bowel Dis 2017;23:38-9.
  • 6. Vernero M, Astegiano M, Ribaldone DG. New onset of inflammatory bowel disease in three patients undergoing il-17a inhibitor secukinumab: a case series. Am J Gastroenterol 2019;114:179-80.
  • 7. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
  • 8. Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019;78:473-9.
  • 9. Deodhar AA, Gladman DD, McInnes IB, van Den Bosch F, Shete A, You R, et al. Post-Marketing Safety of Secukinumab in Adult Patients with Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Cumulative Analysis across >96,000 Patient-Treatment Years Exposure. Arthritis Rheumatol. 2018;70(Suppl 10). [Abstract] Available from: https://acrabstracts. org/abstract/post-marketing-safety-of-secukinumabin- adult-patients-with-psoriasis-psoriatic-arthritis-andankylosing- spondylitis-cumulative-analysis-across-9- 6000-patient-treatment-years-exposure/
  • 10. Kumar P, Monin L, Castillo P, Elsegeiny W, Horne W, Eddens T, et al. Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity 2016;44:659-71.
  • 11. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 2009;58:1152-67.
APA Yazisiz V, uçar i, aslan b, Erbasan Çakır F, terzioglu e (2020). Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. , 300 - 302. 10.46497/ArchRheumatol.2020.7555
Chicago Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. (2020): 300 - 302. 10.46497/ArchRheumatol.2020.7555
MLA Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. , 2020, ss.300 - 302. 10.46497/ArchRheumatol.2020.7555
AMA Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. . 2020; 300 - 302. 10.46497/ArchRheumatol.2020.7555
Vancouver Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. . 2020; 300 - 302. 10.46497/ArchRheumatol.2020.7555
IEEE Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment." , ss.300 - 302, 2020. 10.46497/ArchRheumatol.2020.7555
ISNAD Yazisiz, Veli vd. "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment". (2020), 300-302. https://doi.org/10.46497/ArchRheumatol.2020.7555
APA Yazisiz V, uçar i, aslan b, Erbasan Çakır F, terzioglu e (2020). Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology, 35(2), 300 - 302. 10.46497/ArchRheumatol.2020.7555
Chicago Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology 35, no.2 (2020): 300 - 302. 10.46497/ArchRheumatol.2020.7555
MLA Yazisiz Veli,uçar ismail,aslan bengisu,Erbasan Çakır Funda,terzioglu ender Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology, vol.35, no.2, 2020, ss.300 - 302. 10.46497/ArchRheumatol.2020.7555
AMA Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology. 2020; 35(2): 300 - 302. 10.46497/ArchRheumatol.2020.7555
Vancouver Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment. Archives of Rheumatology. 2020; 35(2): 300 - 302. 10.46497/ArchRheumatol.2020.7555
IEEE Yazisiz V,uçar i,aslan b,Erbasan Çakır F,terzioglu e "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment." Archives of Rheumatology, 35, ss.300 - 302, 2020. 10.46497/ArchRheumatol.2020.7555
ISNAD Yazisiz, Veli vd. "Onset of Inflammatory Bowel Disease Following Interleukin-17A Inhibitor Treatment". Archives of Rheumatology 35/2 (2020), 300-302. https://doi.org/10.46497/ArchRheumatol.2020.7555